A Phase 3 trial of the diabetes drug Farxiga, also known as dapagliflozin, showed it did not help hospitalized Covid-19 patients, AstraZeneca said in a news release Monday.
The trial did not show statistical significance in preventing organ dysfunction and death in hospitalized coronavirus patients who had other risk factors for severe Covid-19.
These risk factors included hypertension, type 2 diabetes, cardiovascular disease and heart failure or chronic kidney disease.
The trial was the first to look at a sodium-glucose co-transporter-2 inhibitor, or SGLT2, in hospitalized Covid-19 patients who have risk factors for developing serious complications.
The US Food and Drink Administration (FDA) describes SGLT2 inhibitors as “a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.”
“DARE-19 provided important data on the potential benefits and risks of using SGLT2 inhibitors to treat hospitalized patients with Covid-19," said Dr. Mikhail Kosiborod, a cardiologist at Saint Luke’s Mid America Heart Institute and principal investigator of DARE-19, in the release.
"While the trial did not achieve statistical significance, the findings are very interesting and valuable, and will inform future clinical science."
The full DARE-19 trial results will be presented at the American College of Cardiology Scientific Sessions in May, AstraZeneca said.